A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–67. 21. Davidson JA, Kannel WB, Lopez-Candales A, Morales L, Moreno PR, Ovalle F, et
al. Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. Ethn Dis. 2007;17:568–73.PubMed 22. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134:550–60.PubMedCrossRef 23. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic Cell Cycle inhibitor performance with bucindolol. Circulation. 1990;82:473–83.PubMedCrossRef 24. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O’Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of
bucindolol versus placebo. Am J Med. 1990;88:223–9.PubMedCrossRef 25. Kaandorp TA, Lamb HJ, Bax JJ, Boersma E, Viergever EP, van der Wall EE, et al. Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance. Heart. 2005;91:1471–2.PubMedCrossRef 26. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei CL. Marked improvement in left ventricular ejection fraction during long-term Selleckchem EPZ015938 beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292–9.PubMedCrossRef medroxyprogesterone 27. de Groote
P, Delour P, Mouquet F, Lamblin N, Dagorn J, Hennebert O, et al. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J. 2007;154:589–95.PubMedCrossRef 28. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899–907.PubMedCrossRef 29. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev. 2010;15:187–96.PubMedCrossRef 30. Mialet PJ, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer Romidepsin cell line differential function and predisposition to heart failure. Nat Med. 2003;9:1300–5.CrossRef 31. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15:227–34.PubMedCrossRef 32. Magnusson Y, Levin MC, Eggertsen R, Nystrom E, Mobini R, Schaufelberger M, et al.